Cargando…
Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases
Fibrosis is a common pathological outcome of chronic injuries, characterized by excessive deposition of extracellular matrix components in organs, as seen in most chronic inflammatory diseases. At present, there is an increasing tendency of the morbidity and mortality of diseases caused by fibrosis,...
Autores principales: | Jia, Min-Qi, Guan, Cha-Xiang, Tao, Jia-Hao, Zhou, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168133/ https://www.ncbi.nlm.nih.gov/pubmed/35677107 http://dx.doi.org/10.1155/2022/5042762 |
Ejemplares similares
-
Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
por: Shi, Xueke, et al.
Publicado: (2020) -
Fibroblasts are not just fibroblasts: clear differences between dermal and pulmonary fibroblasts’ response to fibrotic growth factors
por: Madsen, Sofie Falkenløve, et al.
Publicado: (2023) -
Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease
por: Shen, Yun, et al.
Publicado: (2013) -
Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2021) -
Fibroblast growth factor 21 in metabolic syndrome
por: Yang, Ming, et al.
Publicado: (2023)